Abstract The classical view of biochemical pathways for the formation of biologically active angiotensins continues to undergo significant revision as new data uncovers the existence of important species differences between humans and rodents. The discovery of two novel substrates that, cleaved from angiotensinogen, can lead to direct tissue angiotensin II formation has the potential of radically altering our understanding of how tissues source angiotensin II production and explain the relative lack of efficacy that characterizes the use of angiotensin converting enzyme inhibitors in cardiovascular disease. This review addresses the discovery of angiotensin-(1-12) as an endogenous substrate for the production of biologically active angiotensin peptides by a non-renin dependent mechanism and the revealing role of cardiac chymase as the angiotensin II convertase in the human heart. This new information provides a renewed argument for exploring the role of chymase inhibitors in the correction of cardiac arrhythmias and left ventricular systolic and diastolic dysfunction.
Introduction
The renin-angiotensin system (RAS) is a major physiological regulatory hormonal system of the basic mechanisms that determine tissue perfusion pressure, body fluid volumes, electrolyte balances, and cardiovascular homeostasis [1] [2] [3] . The classic biochemical pathways leading to the generation of biologically active angiotensins has been extensively described in multiple publications. As an endocrine hormonal system, angiotensin II (Ang II) formation in the circulation results from the linear processing of the substrate angiotensinogen (Aogen) produced by the liver, by the renal enzyme renin. The angiotensin I (Ang I) generated product is subsequently converted into Ang II, primarily by angiotensinconverting enzyme (ACE). In the later part of the 1980s, Ferrario's laboratory challenged this universally accepted bio-transformative process with the characterization of angiotensin-(1-7) [Ang-(1-7)] biological actions [4] . The functions of Ang-(1-7) as an endogenous inhibitor of the vasoconstrictor, neurogenic, trophic, prothrombotic, and profibrotic actions of Ang II are extensively reviewed elsewhere [3, [5] [6] [7] [8] [9] .
The further demonstration that cells have the intrinsic ability to express the genes accounting for Ang II production greatly expanded knowledge of the importance of the system in modulating cellular functions in both health and disease. As reviewed by Paul [10] , the expression of tissue-angiotensin peptides' generation led to a significant expansion of knowledge regarding their function as paracrine/intracrine/autocrine regulators of physiological functions and their role in human diseases. The expanded tissue RAS vocabulary now includes the characterization of ACE2 as an enzyme cleaving Ang I to form Ang-(1-9) and Ang-(1-7) from Ang II [11, 12] , the opposing actions of the AT 2 -receptor on Ang II AT 1 mediated actions [13, 14•, 15] , and more recently, the detection of a new Ang-(1-7)-derivative that couples to a Mas-related type D (MrgD) receptor [16•, 17] . A new and intriguing observation is the demonstration that Ang-(1-9) may have biological actions comparable to those associated with Ang-(1-7) [18] [19] [20] .
While knowledge of non-renin dependent alternate enzymatic mechanisms for Ang I formation, as well as non-ACE pathways for Ang II from Ang I, are described in the literature, scant attention has been paid to their significance. The overwhelming assumption that the beneficial clinical results achieved with the use of inhibitors of ACE or prevention of Ang II binding through the use of AT 1 receptor antagonists has led to the opinion that these alternate mechanisms for Ang II production are not relevant. Although a rich literature shows benefits of blockade using direct renin inhibitors (DRI), ACE inhibitors or Ang II receptor blockers (ARBs), the overall results related to a delay or reversal of target organ damage or morbid events has fallen short of expectations. This issue has come of age from the analysis of large clinical trials for hypertension, strokes, and heart failure [21], as well as atrial fibrillation (AF) [22] . Turnbull et al. 's [21] report, based on the analysis of 31 trials with 190,606 participants, showed "no clear difference between age groups in the effects of lowering blood pressure or any difference between the effects of the drug classes on major cardiovascular events." These findings were further underscored by a more focused analysis of potential differences in cardiovascular outcomes between ACE inhibitors and ARBs. In this meta-regression analysis of data from 26 large-scale trials, the investigators found no evidence of any blood pressure-independent effects of either ACE inhibition or Ang II receptor blockade [23] . The potential for these treatment approaches to account for incomplete blockade of Ang II actions or synthesis is not an explanation for these outcomes, because combination of ARB and ACE inhibitors showed no further benefits in the large ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, in which ramipril was combined with telmisartan [24, 25] , the Altitude trial which combined aliskiren with valsartan [26, 27], or in a systematic large meta-analysis of studies of patients with symptomatic left ventricular dysfunction [28] . While we are not denying the proven benefits of ACE inhibitors and ARBs in the reduction of target-organ damage and the occurrence of clinical events, the benefit appears to be primarily the results of their antihypertensive effects (i.e., magnitude of blood pressure lowering), rather than the additional benefit that could be gained from blockade of tissue Ang II. These findings suggest that the Ang II pathological actions may occur at sites that are not effectively reached by the current RAS blockers, or that for the case of renin and ACE, these enzymes are not critical in the formation of Ang II in humans. This review will bring these questions to the forefront by asking:
1) Is chymase in humans more important than ACE in Ang II production? 2) Is renin the only enzyme initiating Aogen biotransformation toward angiotensin peptides generation?
The relevance of these questions has been brought to bear by the recent discoveries of alternate substrates for Ang II production, Big angiotensin-25 [Ang- (1- . In these conditions, the dodecapeptide caused blood pressure responses consistent with Ang II-dependent modulation of baroreflexes or sympathoexcitation. Additional studies of Ang-(1-12) actions in the heart and vasculature supported its role as a functional source for tissue Ang II production, as the peptide constricted coronary arteries with no significant effect on left-ventricular contractility and also impaired recovery from global ischemia [39] . In the periphery, Prosser et al. [40] showed Ang-(1-12) vasoconstrictor activity in the isolated descending thoracic aorta, right and left common carotid arteries, abdominal aorta and superior mesenteric artery. Altogether, these studies demonstrated that Ang-(1-12) serves as a pathway for the generation of Ang peptides, a biotransformation mechanism that may be of relevance in situations of suppressed renin activity, as well as functioning as an intracellular precursor for the generation of biologically active angiotensin peptides.
While early studies seem to indicate that Ang-(1-12) conversion into Ang II was mediated by ACE, other studies implicated chymase as contributing to its metabolism [34, 39, 40] . This dual processing may be related to the site for Ang-(1-12) metabolism, with ACE having a significant role in the systemic circulation [41] and chymase a more prominent role in the heart [39, 42•]. The divergency of Ang-(1-12) metabolic pathways might be highly tissue specific, as a report suggested that neprilysin could also function as Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) convertase in the kidney [43] . Neprilysin is a major metalloproteinase member of the M13 family of proteases that also includes endothelin-converting enzyme (ECE) [44] . Since neprilysin activity in the kidney is very high compared to renal ACE activity [45•], the data suggesting that neprilysin converts Ang-(1-12) into Ang I will need to be verified in studies in which more selective inhibitors of neprilysin are utilized. On the other hand, divergency in metabolic pathways is not surprising, since past work showed the existence of different enzymatic routes for the generation of angiotensin peptides, different receptors distribution patterns in different tissues, and alternate mechanisms influencing receptor regulation in cardiovascular functions and remodeling [10, 14•] . These characteristics support the dual role of the RAS as both a circulating hormonal and a tissue-specific system, wherein the generation of angiotensin substrates serves not only autocrine/ paracrine, but also intracrine functions [14•, 46, 47, 48•] .
The discovery of Ang-(1-12) as an Ang peptides forming substrate has generated new directions in exploring the role of non-renin pathways for Ang II production. Studies suggest that Ang II is produced both extracellularly and intracellularly to exert tropic and profibrotic actions in the heart [49] [50] [51] . Ang II actions in the heart would depend upon the site at which the peptide is generated, the proximity of the enzyme and substrate needed for the production of the peptide, as well as the turnover of these components [52] . One additional consideration is whether or not the processes occur outside or inside the cardiac myocytes. This is a critical factor, as ACE inhibitors or ARBs do not reach the intracellular compartment at which Ang II acts [49, 53, 54•, 55, 56] . In keeping with these findings, we showed that administration of lisinopril, losartan or both drugs combined did not alter myocardial Ang II content while having the expected effects on plasma Ang II [57] . The studies showing the presence of Ang-(1-12) and chymase protein in cardiac human and rodent myocytes suggest the possibility that this is an intracellular mechanism for Ang II production that will not be interrupted by RAS blockade.
Species differences in the enzymatic mechanisms by which Ang-(1-12) is processed into Ang II are now strongly suggested by a series of comparative studies that explored this issue in heart tissue from normal and diseased subjects [5, 58••, 59••] . In these studies, we showed that chymase was the sole enzyme converting Ang-(1-12) into Ang I and Ang II. Of particular interest was the finding that Ang-(1-12) was directly converted to Ang II in plasma membranes obtained from left ventricle (LV) of normal subjects [59••] . These data buttressed our concept that Ang II formation is compartmentalized, with chymase being the major Ang II forming mechanism in the cardiac interstitium while ACE acts as the major Ang II forming mechanism in the intravascular space.
Cardiac chymase is important in adverse LV remodeling post-myocardial infarction [60, 61] , atherosclerosis [62, 63] , type 2 diabetes [64] , and heart failure [65] [66] [67] . Furthermore, increased LV mast cells and chymase were found in experimental models of pure volume overload induced by an aortocaval fistula in rats, isolated mitral regurgitation (MR) in dogs [68] [69] [70] [71] 72 ••] and estrogen-sensitive diastolic dysfunction in ovariectomized mRen2.Lewis rats [73•, 74] . All mammals have the Ang II-forming α-chymase isoform [75, 76] . However, only the baboon, macaque, and dog have a single α-chymase; while the mouse, rat, pig, and rabbit have the additional β-chymase isoform that degrades Ang II [75, 77, 78] . There are numerous studies demonstrating the beneficial effects of chymase inhibitors that target the cleavage site on the human chymase, in species having the β-chymase isoform. We have shown such an effect in the mouse, where an orally active human chymase inhibitor decreases interstitial fluid Ang II formation in the C56B6 mouse [61] . Thus, species with the β-chymase isoform do have baseline net chymase-mediated Ang II formation that increases with cardiovascular stress. Nevertheless, much has been written about the suitability and clinical relevance of rodent species, in particular, for the study of chymase-mediated effects on cardiovascular remodeling because of the lack of the β-chymase isoform in the human and the specificity of the various human targeted chymase inhibitors across various mammalian species. These points are underscored by our studies, as chymase was shown to be the enzyme cleaving Ang- It is important to stress that chymase activity is only detected in tissues and not in the circulation. It has been suggested that chymase released from activated mast cells is mostly trapped as a cage-like structure by an α2-macroglobulin (α2-M). This trapping may prevent its interactions with large protein substrates and inhibitors (like serpins) [79] . This interaction does not seem to interfere with the ability of chymase to access small peptides such as Ang I, since it has been reported that α2-M trapped chymase is able to convert Ang I into Ang II [79] . Therefore, the biochemical and signaling mechanisms forming the Ang II within the cellular microenvironment are accounted for alternate enzymatic pathways that are different than those in the circulation and unable to be blocked by either ACE inhibitors or ARBs. Our recent studies in neonatal rat myocytes [42•] and human atrial appendages [58••] documented the presence of Ang-(1-12) and chymase in the diseased cardiocytes. We postulated that the intracellular formation of Ang II via this chymase pathway is independent of and unaffected by inhibition of Ang II production by ACE inhibitors or blockade of AT 1 receptors [5] . Consequently, neither of these approaches will exert complete inhibition of Ang II cellular activities, as these agents do not penetrate beyond the cell membrane.
Synthesis and Cellular Ang-(1-12) Expression
Our previous studies showed high cardiac concentration of Ang-(1-12) in SHR as compared to normotensive WKY [31], increased Ang-(1-12) content in anephric normotensive rats [80] and cardiac formation of Ang I, Ang II and Ang-(1-7) through cleavage of Ang-(1-12) via a non-renin pathway in isolated hearts of three normotensive (Sprague Dawley, Lewis and WKY) and two hypertensive (congenic mRen2.Lewis and SHR) rat strains [81] . Increased concentrations of endogenously expressed Ang-(1-12) and chymase, as well as chymase activity, were also found in neonatal cultured cardiac myocytes of SHR compared to WKY [42•].
Existence of an intrinsic mechanism for the intracellular generation of Ang II in cardiac myocytes that is independent from uptake from the circulation or the interstitial environment has been demonstrated by others [55, [82] [83] [84] , but no data exists as to whether intracrine Ang II formation follows the canonical enzymatic pathways and intermediate peptides described in the circulation, or whether it is generated by alternate non-canonical mechanism whereby Aogen is processed to intermediate substrates [i.e., Ang-(1-12)] independent of renin and ACE pathways. While both renin and Aogen are not highly expressed in heart tissue, cardiac content of Ang II has been reported to be > 100 time higher than in the plasma [75] . Whether these high concentrations are a reflection of local synthesis in the immediate interstitial microenvironment or intracellularly remains to be firmly established [52] . We have shown increased incorporation of intact Ang- In the characterization of the non-canonical pathways accounting for the intracrine or paracrine production of Ang II, there is a need to uncover what enzymes and intermediate substrates account for the generation of Ang-(1-12) from Aogen. This area is just beginning to be explored. Our past studies demonstrate that renin is not involved in Ang-(1-12) metabolism, but these findings do not exclude that renin may serve as an Ang-(1-12) forming enzyme. Past studies showed that several serine proteases, such as tonin and cathepsin G, hydrolyze Ang II precursors [85] [86] [87] [88] . Of relevance to the current topic, Ang-(1-12) was shown to be generated from the synthetic tetradecapeptide Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) in rat aorta tissue [89] . Ang-(1-12) formation from Ang-(1-14) was almost 7-fold higher than the formation of Ang I by rat aorta tissue [89] . Work in progress from our laboratory suggests that cardiac Ang-(1-12) may be cleaved from Aogen by a member of the kallikrein enzyme system [5, 90] . This observation is in keeping with the early demonstration that trypsin could generate Ang II directly from human plasma protein in the absence of converting enzyme [91, 92] . This may not be the sole pathway for tissue formation of bioactive angiotensin peptides, as Nagata and collaborators [29••] have recently reported the existence of another precursor named Big angiotensin-25. This new member of the RAS isolated from human urine, consists of the first 25 amino acids of the Aogen molecule, and contains a glycosyl chain and added cysteine. Ang-(1-25) is rapidly cleaved by chymase and was detected in a wide range of human organs and tissues (including left ventricle cardiocytes). This new finding raises the question as to whether Ang-(1-25) may be an immediate precursor for Ang-(1-12) generation. Preliminary observations from our laboratory that the glycosylated form of Ang-(1-25) is not expressed in rodents are in keeping with the overall hypothesis that the biochemical mechanisms for tissue Ang II formation in humans are distinctly different than those in rodents. That this point has not been sufficiently documented and understood by the scientific community is an important issue, as it has direct implications in terms of present and future approaches to treatment of cardiovascular disease.
Summary and Conclusions:
Advances in the biochemical physiology of tissue RAS brought to the forefront the presence of alternate pathways for the generation and metabolism of angiotensin peptides. Adding to this knowledge, our new findings demonstrate the existence of additional alternate mechanisms for the formation of angiotensin peptides upstream from Ang I. The two questions posed in the Introduction can thus be appropriately answered. Chymase is the critical Ang II forming enzyme in humans, and ACE is not the sole enzyme forming Ang II.
A highly productive effort to dissect the functional role of Ang-(1-12) as an alternate substrate for Ang II generation has led us to uncover highly specific tissue/cellular dependent mechanisms that through non-renin pathways mediate the intracellular actions of Ang II. The translational research in rodents and human cardiac tissue reveals species-specific regulatory substrates for Ang II formation. These findings may explain the relative failure of current approaches using ACE inhibitors and ARBs to suppress the pathological actions of Ang II in cardiovascular disease, as these drugs acting on the cell surface do not reach the intracellular sites at which biotransformation of the substrates [Ang-(1-12)] occurs.
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